Vir Biotechnology completes Phase 2 SOLSTICE clinical trial ahead of schedule

Vir Biotechnology announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta, CHD, virus has completed enrollment of its current cohorts one month earlier than anticipated. This includes over 60 participants in two additional cohorts – one evaluating tobevibart given every 2 weeks and the other evaluating the combination of tobevibart and elebsiran given every 4 weeks. Initial data are expected in the second quarter of 2024. “The swift completion of enrollment ahead of expectations reflects the strong patient and physician interest being generated, and the urgent need for new treatment options for the millions of underserved hepatitis delta patients,” said Carey Hwang, M.D., Ph.D., Vir‘s Senior Vice President, Clinical Research. “We are proud of the continued progress towards our goal of developing a safe and efficacious chronic therapy to address the significant treatment gap and look forward to reporting additional data on these participants this year.”